{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:20:11Z","timestamp":1793193611942,"version":"4.5.0"},"reference-count":66,"publisher":"Royal College of Psychiatrists","issue":"1","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"unspecified","delay-in-days":34,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. Psychiatr."],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"S0924933824018030_sec1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used due to their profound efficacy in glycemic control and weight management. Real-world observations have revealed potential neuropsychiatric adverse events (AEs) associated with GLP-1RAs. This study aimed to comprehensively investigate and characterize these neuropsychiatric AEs with GLP-1RAs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0924933824018030_sec2\" sec-type=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed GLP-1RA adverse reaction reports using the FDA Adverse Event Reporting System database. Disproportionality analysis using reporting odds ratio (ROR) identified eight categories of neuropsychiatric AEs associated with GLP-1RAs. We conducted descriptive and time-to-onset (TTO) analyses and explored neuropsychiatric AE signals among individual GLP-1RAs for weight loss and diabetes mellitus (DM) indications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0924933824018030_sec3\" sec-type=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 25,110 cases of GLP-1RA-related neuropsychiatric AEs. GLP-1RAs showed an association with headache (ROR 1.74, 95% confidence interval [CI] 1.65\u20131.84), migraine (ROR 1.28, 95%CI 1.06\u20131.55), and olfactory and sensory nerve abnormalities (ROR 2.44, 95%CI 1.83\u20133.25; ROR 1.69, 95%CI 1.54\u20131.85). Semaglutide showed a moderate suicide-related AEs signal in the weight loss population (ROR 2.55, 95%CI 1.97\u20133.31). The median TTO was 16\u00a0days (interquartile range: 3\u201366\u00a0days).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0924933824018030_sec4\" sec-type=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study, we identified eight potential neuropsychiatric adverse events (AEs) associated with GLP-1RAs and, for the first time, detected positive signals for migraine, olfactory abnormalities, and sensory abnormalities. We also observed positive suicide-related signals of semaglutide, in weight loss population. This study provides a reliable basis for further investigation of GLP-1RA-related neuropsychiatric AEs. However, as an exploratory study, our findings require confirmation through large-scale prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1192\/j.eurpsy.2024.1803","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T01:10:26Z","timestamp":1738631426000},"source":"Crossref","is-referenced-by-count":36,"title":["Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database"],"prefix":"10.1192","volume":"68","author":[{"given":"Wenchao","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-9217","authenticated-orcid":false,"given":"Shihan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"S0924933824018030_r60","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789"},{"key":"S0924933824018030_r18","first-page":"2292461","article-title":"Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer\u2019s and Parkinson\u2019s diseases","author":"Rhea","year":"2023","journal-title":"Tissue Barriers"},{"key":"S0924933824018030_r11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037928"},{"key":"S0924933824018030_r48","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15440-8"},{"key":"S0924933824018030_r5","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1292125"},{"key":"S0924933824018030_r49","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-024-04657-3"},{"key":"S0924933824018030_r66","unstructured":"[66] FDA. Update on FDA\u2019s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity; 30 January 2024. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type (accessed 2 June 2024)."},{"key":"S0924933824018030_r12","unstructured":"[12] European Medicine Agency. EMA statement on ongoing review of GLP-1 receptor agonists; 11 July 2023. Available from: https:\/\/www.ema.europa.eu\/en\/news\/ema-statement-ongoing-review-glp-1-receptor-agonists (accessed 2 June 2024)."},{"key":"S0924933824018030_r54","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-226346"},{"key":"S0924933824018030_r51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2007.01765.x"},{"key":"S0924933824018030_r27","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6048"},{"key":"S0924933824018030_r4","unstructured":"[4] Food and Drug Administration. FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight; 8 March 2024. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or (accessed 2 June 2024)."},{"key":"S0924933824018030_r14","unstructured":"[14] Food and Drug Administration. Label for OZEMPIC; March 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/209637Orig1s009lbl.pdf (accessed 2 June 2024)."},{"key":"S0924933824018030_r37","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2023.2474"},{"key":"S0924933824018030_r57","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0849"},{"key":"S0924933824018030_r65","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13547"},{"key":"S0924933824018030_r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2024.07.001"},{"key":"S0924933824018030_r26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12963"},{"key":"S0924933824018030_r53","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2019.0303"},{"key":"S0924933824018030_r19","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133429"},{"key":"S0924933824018030_r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101967"},{"key":"S0924933824018030_r64","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.765446"},{"key":"S0924933824018030_r42","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2022.05.003"},{"key":"S0924933824018030_r46","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12895"},{"key":"S0924933824018030_r29","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.26"},{"key":"S0924933824018030_r1","unstructured":"[1] World Obesity Federation. World obesity atlas 2023. Available from: https:\/\/data.worldobesity.org\/publications\/?cat=19 (accessed 2 June 2024)."},{"key":"S0924933824018030_r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2019.100822"},{"key":"S0924933824018030_r38","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03274-6"},{"key":"S0924933824018030_r20","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0952"},{"key":"S0924933824018030_r40","doi-asserted-by":"publisher","DOI":"10.1080\/13548506.2016.1164870"},{"key":"S0924933824018030_r16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802206"},{"key":"S0924933824018030_r23","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.2"},{"key":"S0924933824018030_r34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1330936"},{"key":"S0924933824018030_r10","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1238353"},{"key":"S0924933824018030_r39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2012.07.010"},{"key":"S0924933824018030_r3","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.140"},{"key":"S0924933824018030_r13","unstructured":"[13] Food and Drug Administration. Potential signals of serious risks\/new safety information identified by the FDA Adverse Event Reporting System (FAERS); 21 June 2024. Available from: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse (accessed 2 June 2024)."},{"key":"S0924933824018030_r9","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1937"},{"key":"S0924933824018030_r62","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023830"},{"key":"S0924933824018030_r35","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-023-01694-7"},{"key":"S0924933824018030_r7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.721135"},{"key":"S0924933824018030_r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102427"},{"key":"S0924933824018030_r55","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2024.02.003"},{"key":"S0924933824018030_r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2012.11.013"},{"key":"S0924933824018030_r25","doi-asserted-by":"publisher","DOI":"10.1007\/s40211-019-0302-9"},{"key":"S0924933824018030_r36","doi-asserted-by":"publisher","DOI":"10.3390\/ph16070994"},{"key":"S0924933824018030_r15","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-021-00344-4"},{"key":"S0924933824018030_r52","doi-asserted-by":"publisher","DOI":"10.3390\/genes13101845"},{"key":"S0924933824018030_r59","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01270"},{"key":"S0924933824018030_r43","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.14115"},{"key":"S0924933824018030_r58","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2023.101470"},{"key":"S0924933824018030_r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.113998"},{"key":"S0924933824018030_r21","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-010-1874-x"},{"key":"S0924933824018030_r17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-13-33"},{"key":"S0924933824018030_r45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141921"},{"key":"S0924933824018030_r30","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100258"},{"key":"S0924933824018030_r31","unstructured":"[31] Novonordisk. 2023 annual report. Available from: https:\/\/www.novonordisk.com\/content\/dam\/nncorp\/global\/en\/investors\/irmaterial\/annual_report\/2024\/novo-nordisk-annual-report-2023.pdf (accessed 4 June 2024)."},{"key":"S0924933824018030_r47","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2021.0278"},{"key":"S0924933824018030_r6","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa285"},{"key":"S0924933824018030_r2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01301-6"},{"key":"S0924933824018030_r50","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01337-0"},{"key":"S0924933824018030_r56","doi-asserted-by":"publisher","DOI":"10.3390\/ph17020147"},{"key":"S0924933824018030_r61","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02672-2"},{"key":"S0924933824018030_r41","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2584"},{"key":"S0924933824018030_r44","doi-asserted-by":"publisher","DOI":"10.1113\/JP272322"},{"key":"S0924933824018030_r63","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2295397"}],"container-title":["European Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924933824018030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T01:10:32Z","timestamp":1738631432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924933824018030\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"alternative-id":["S0924933824018030"],"URL":"https:\/\/doi.org\/10.1192\/j.eurpsy.2024.1803","relation":{},"ISSN":["0924-9338","1778-3585"],"issn-type":[{"value":"0924-9338","type":"print"},{"value":"1778-3585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"e20"}}